May 8, 2019
Sanofi K.K., the Japan arm of Sanofi S.A., said on May 7 that it has completed the merger of Bioverativ Japan as of May 1, taking over its hemophilia treatments Eloctate (efraloctocog alfa) and Alprolix (eftrenonacog alfa). Bioverativ Japan started...read more